• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

    85.78 +0.25 (+0.29%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,694,403
    Open 86.31
    Bid (Size) 85.74 (400)
    Ask (Size) 85.78 (3,300)
    Prev. Close 85.53
    Today's Range 82.77 - 86.64
    52wk Range 15.01 - 95.49
    Shares Outstanding 105,736,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session. ↗
    Via Chartmill

    Performance

    YTD
    +26.5%
    +26.5%
    1 Month
    +6.6%
    +6.6%
    3 Month
    +16.5%
    +16.5%
    6 Month
    +28.4%
    +28.4%
    1 Year
    +429.5%
    +429.5%

    More News

    Read More
    Gapping stocks in Wednesday's session ↗
    Via Chartmill
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat ↗
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
    Via MarketBeat
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗
    Via MarketBeat
    News headline image
    Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near ↗
    Via MarketBeat
    News headline image
    Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
    Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
    What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 85.78
    When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 07/28/26 04:00 PM ET
    What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 9.07B
    How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
    Arrowhead Pharmaceuticals, Inc. - Common Stock has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.